Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lingze (also known as Lingze tablets) is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Yiling Pharmaceutical. It is primarily indicated for the treatment of benign prostatic hyperplasia (BPH) and chronic prostatitis. The formulation typically includes ingredients such as *Ganoderma lucidum*, *Salvia miltiorrhiza*, *Curcuma phaeocaulis*, and *Fructus Rosae Laevigatae*. Its therapeutic mechanism in TCM terms involves tonifying the kidney, resolving blood stasis, and promoting diuresis to improve lower urinary tract symptoms (LUTS). It is frequently evaluated in clinical trials in combination with Western medications like alpha-1 blockers (e.g., doxazosin) to enhance efficacy in managing BPH.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lingze.